EXACT Sciences Corporation (EXAS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, EXACT Sciences Corporation (EXAS) has a cash flow conversion efficiency ratio of 0.063x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($151.69 Million) by net assets ($2.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EXACT Sciences Corporation (EXAS) defensive interval to measure how many days the company can operate on defensive assets alone.
EXACT Sciences Corporation - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how EXACT Sciences Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
EXACT Sciences Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EXACT Sciences Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MPI Corporation
TWO:6223
|
0.102x |
|
Allegheny Technologies Incorporated
NYSE:ATI
|
0.165x |
|
STERIS plc
NYSE:STE
|
0.042x |
|
HP Inc
NYSE:HPQ
|
0.112x |
|
Grupo Carso S.A.B. de C.V
MX:GCARSOA1
|
-0.002x |
|
Adani Energy Solutions Limited
NSE:ADANIENSOL
|
0.151x |
|
Fidelity National Information Services Inc
NYSE:FIS
|
0.076x |
|
Sinoma Science & Technology Co Ltd
SHE:002080
|
0.061x |
Annual Cash Flow Conversion Efficiency for EXACT Sciences Corporation (1999–2025)
The table below shows the annual cash flow conversion efficiency of EXACT Sciences Corporation from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see EXAS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.40 Billion | $491.44 Million | 0.205x | +133.54% |
| 2024-12-31 | $2.40 Billion | $210.54 Million | 0.088x | +76.57% |
| 2023-12-31 | $3.15 Billion | $156.12 Million | 0.050x | +167.57% |
| 2022-12-31 | $3.04 Billion | $-223.56 Million | -0.073x | -143.42% |
| 2021-12-31 | $3.39 Billion | $-102.24 Million | -0.030x | -149.43% |
| 2020-12-31 | $2.24 Billion | $136.48 Million | 0.061x | +225.11% |
| 2019-12-31 | $2.29 Billion | $-111.66 Million | -0.049x | +52.07% |
| 2018-12-31 | $680.94 Million | $-69.33 Million | -0.102x | +26.13% |
| 2017-12-31 | $520.42 Million | $-71.72 Million | -0.138x | +64.47% |
| 2016-12-31 | $335.30 Million | $-130.07 Million | -0.388x | +5.39% |
| 2015-12-31 | $326.86 Million | $-134.02 Million | -0.410x | -46.44% |
| 2014-12-31 | $288.98 Million | $-80.91 Million | -0.280x | +3.58% |
| 2013-12-31 | $135.32 Million | $-39.30 Million | -0.290x | +35.16% |
| 2012-12-31 | $98.59 Million | $-44.16 Million | -0.448x | -34.39% |
| 2011-12-31 | $83.50 Million | $-27.82 Million | -0.333x | -97.19% |
| 2010-12-31 | $79.75 Million | $-13.48 Million | -0.169x | +91.85% |
| 2009-12-31 | $6.09 Million | $-12.64 Million | -2.074x | -163.85% |
| 2008-12-31 | $-2.43 Million | $-7.90 Million | 3.249x | +333.01% |
| 2007-12-31 | $6.29 Million | $-8.77 Million | -1.394x | -71.59% |
| 2006-12-31 | $14.96 Million | $-12.15 Million | -0.813x | -25.18% |
| 2005-12-31 | $24.62 Million | $-15.98 Million | -0.649x | -16.44% |
| 2004-12-31 | $37.98 Million | $-21.17 Million | -0.557x | +50.85% |
| 2003-12-31 | $12.23 Million | $-13.87 Million | -1.134x | -265.01% |
| 2002-12-31 | $38.35 Million | $-11.92 Million | -0.311x | -15.71% |
| 2001-12-31 | $58.97 Million | $-15.84 Million | -0.269x | +6.91% |
| 2000-12-31 | $27.70 Million | $-7.99 Million | -0.289x | +72.39% |
| 1999-12-31 | $4.41 Million | $-4.61 Million | -1.045x | -- |
About EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence S… Read more